Skip to main content

Advertisement

SpringerLink
Log in

Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents

  • Original Articles
  • Published:
Gastroenterologia Japonica Aims and scope Submit manuscript

Summary

5-fluorouracil analogs investigated in this study include a combination of uracil and Ftorafur (UFT), Ethyl (±)-t-butoxy-5 -fluoro-hexahydro-2,4-dioxopyrimidine r-5-carboxylate (TAC-278), and 5′-deoxy-5-fluorouridine (5′-DFUR). In a total of 45 patients with gastric cancer, tumor tissue level of 5-fluorouracil (5-FU) was determined at 2, 4, 6, 8, and 12 hours following the oral administration of drug, using a resected stomach specimen as material. As a result, it was demonstrated that oral administration of 200 mg/m2 of UFT maintained above 0.05jΜg/g (minimum inhibitory concentration: MIC) of 5-FU in tumor tissues over 12 hours in 11 of 13 patients. On the contrary, 133 mg/m2 of TAC-278, and 200mg/m2 or 300mg/m2 of 5′-DFUR (which is activated by thymidine phosphorylase in man) did not produce an effective 5-FU concentration in tumor tissues. Serum 5-FU level was high in order of TAC-278, UFT, and 5′-DFUR. Clinical response rates obtained with UFT (200mg/m2 twice a day), or TAC-278 (133–200mg/m2, 3 times daily) were 27.5% (49 of 178 cases), and 8.3% (3 of 36 cases, by Koyama et al.), respectively. Fisher’s direct probability test revealed that there was a significant difference (p<0.05) between them in the response rate. It was considered that the measurement of concentration of anticancer drugs in tumor tissues might provide us useful information for the designing of chemotherapy of gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kimura K: Chemotherapy of cancer. Nippon IjiShimpo, No 2766: 3, 1977 (Jpn)

  2. Ikenaka K, et al: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70: 353, 1979

    PubMed  CAS  Google Scholar 

  3. Suzuki S, et al: Distribution of 5′-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann 71: 238, 1980

    PubMed  CAS  Google Scholar 

  4. Niwa M, et al: A simple and convenient assay method for phosphorolysis of 5′-deoxy-5-fluorouridine. Gann 72:965, 1981

    Google Scholar 

  5. Maehara Y, et al: Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gann 72: 824, 1981

    PubMed  CAS  Google Scholar 

  6. Fujii S, et al: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and l-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763, 1978

    PubMed  Google Scholar 

  7. Fujii S, et al: Effects of coadministration of uracil or cytosine on the antitumor activity of clinical doses of l(2tetrahydrofuryl)-5-fluorouracil (FT) and level of 5-fluorouracil in rodents. Gann 70: 209, 1979

    PubMed  CAS  Google Scholar 

  8. Mukherjee L, Heidelberger C: Studies on fluorinated pyrimidine. IX The degradation of 5-fluorouracil-6-C14. J Biol Chem 235:433, 1960

    PubMed  CAS  Google Scholar 

  9. Jato J, Windheuser JJ: 5-fluorouracil and derivatives in cancer chemotherapy. III In vitro enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2′-deoxyuridine(FUDR). J Pharm Sci 62: 1975, 1973

    Article  PubMed  CAS  Google Scholar 

  10. Sullivan RD, et al: Antimetabolite-metabolite combination cancer chemotherapy: Effect of intra-arterial methotrexate-intramuscular citrovolum factor therapy in human cancer. Cancer 122: 1248, 1959

    Article  Google Scholar 

  11. Stoller RG, et al: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemotherapy Rep 6: 19, 1975

    Google Scholar 

  12. Jato JG, et al: Effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and fluorouridine. J Pharm Sci 64: 943, 1975

    Article  PubMed  CAS  Google Scholar 

  13. Djerassi I: Methotrexate and citrovolum factor rescue in the management of childhood lymphosarcoma (Non-Hodgikin’s lymphoma); Prolonged unmaintained remissions. Cancer 38: 1043, 1976

    Article  PubMed  CAS  Google Scholar 

  14. Taguchi T, et al: Effect of uracil on the antitumor activity of futraful. Gan to Kagakuryoho 5: 1161, 1978 (Jpn)

    CAS  Google Scholar 

  15. Taguchi T, et al: Determination of 5-fluorouracil levels in tumor, blood, and other tissues. Gan to Kagakuryoho 5: 1167, 1978 (Jpn)

    CAS  Google Scholar 

  16. Semon JH, Grindey, GB: Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. Cancer Res 38: 2905, 1978

    PubMed  CAS  Google Scholar 

  17. Taguchi T, Nakano, Y: Attainability of anticancer drugs into the tumor. -UFT-therapy-. Gan to Kagakuryoho 6: 257, 1979 (Jpn)

    CAS  Google Scholar 

  18. Kirkwood, JM, et al: Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a phase I trial. Cancer Res 40: 107, 1980

    PubMed  CAS  Google Scholar 

  19. Grossie Jr, VB, Loo TL: Effect of thymidine on the toxicity and antitumor activity of ftorafur. Cancer Treatment Rep 65: 1087, 1981

    CAS  Google Scholar 

  20. Majima H: Phase 1 and preliminary phase II clinical studies of ethyl (±)-t-butoxy-5-fluoro-2,4-dioxohexahydropyrimidine r-5-carboxylate (TAC-278). Gan to Kagakuryoho 8: 1125, 1981 (Jpn)

    Google Scholar 

  21. Marunaka T, et al: High-pressure liquid chromato graphic determination of ftorafur [l-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur. J Pharm Sci 69: 1296, 1980

    Article  PubMed  CAS  Google Scholar 

  22. Marunaka T, Umeno Y: Gas Chromatographic determination of 5-fluorouracil as metabolite of new 5-fluorouracil derivatives. Chem Pharm Bu-1, 5, 1982 (in press)

  23. Kimura K, et al: Clinical basis of chemotherapy for gastric cancer with uracil and l-(2-tetrahydrofuryl)-5-fluorouracil. Gastroenterol Jpn 15: 324, 1980

    PubMed  CAS  Google Scholar 

  24. Saito T: Cancer chemotherapy of solid tumors—with special reference to criteria for the evluation of chemotherapy—. Jpn J Cancer Clin 26: 632, 1980 (Jpn)

    Google Scholar 

  25. Shirasaka T, et al: Pyrimidine nucleoside phosphorylase in rodents and human. Gan to Kagakuryoho 8: 282, 1981 (Jpn)

    Google Scholar 

  26. Taguchi T, et al: Clinical trial of TAC-278 by cooperative study group. Gan to Kagakuryoho 8: 1885, 1981 (Jpn)

    Google Scholar 

  27. Laskin JD, et al: Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 39: 383, 1979

    PubMed  CAS  Google Scholar 

  28. Evans RM, et al: Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and human cells. Cancer Res 40: 4113, 1980

    PubMed  CAS  Google Scholar 

  29. Kimura K, Suga S: Clinical application and limitation of anticancer agents. Rynsho to Kenkyu (Jpn J Clin Exptl Med) 58: 2401, 1981 (Jpn)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Nagoya Hospital, Naka-ku, 460, Nagoya, Japan

    Shoji Suga M.D., Kiyoji Kimura M.D., Kichiro Isobe M.D., Yuichi Yoshida M.D., Toru Takada M.D., Akihiko Sato M.D., Toshimasa Kuwabara M.D. & Hiroaki Iwase M.D.

  2. Yokoyama Gastrointestinal Hospital, Nakaku, 460, Nagoya, Japan

    Yasuhisa Yokoyama M.D.

Authors
  1. Shoji Suga M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiyoji Kimura M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhisa Yokoyama M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kichiro Isobe M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichi Yoshida M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toru Takada M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihiko Sato M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshimasa Kuwabara M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroaki Iwase M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by a Grant from the Ministry of Health and Welfare, and the Ministry of Education, Science and Culture, and in part by a Grant from the Japanese Foundation for Multidisciplinary Treatment of Cancer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suga, S., Kimura, K., Yokoyama, Y. et al. Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents. Gastroenterol Jpn 17, 295–300 (1982). https://doi.org/10.1007/BF02774574

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02774574

Key Words

Search

Navigation